BR112019023109A2 - Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo - Google Patents

Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo Download PDF

Info

Publication number
BR112019023109A2
BR112019023109A2 BR112019023109-9A BR112019023109A BR112019023109A2 BR 112019023109 A2 BR112019023109 A2 BR 112019023109A2 BR 112019023109 A BR112019023109 A BR 112019023109A BR 112019023109 A2 BR112019023109 A2 BR 112019023109A2
Authority
BR
Brazil
Prior art keywords
nadph oxidase
mediated
affection
syndrome
disorder
Prior art date
Application number
BR112019023109-9A
Other languages
English (en)
Inventor
Kumar Sukeerthi
Thomas Abraham
Sundarlal Chaudhari Sachin
Atmaram Gharat Laxmikant
Khairatkar-Joshi Neelima
Manish Shah Daisy
Mukhopadhyay Indranil
Original Assignee
Glenmark Pharmaceuticals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals S.A. filed Critical Glenmark Pharmaceuticals S.A.
Publication of BR112019023109A2 publication Critical patent/BR112019023109A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

o presente pedido se refere a compostos de heteroarila e heterocíclicos fundidos substituídos úteis como inibidores de fosfato dinucleotídico de adenina de nicotinamida oxidase (inibidores de nadph oxidase), processos para sua preparação, composições farmacêuticas que compreendem os compostos, e o uso dos compostos ou das composições no tratamento ou prevenção de várias doenças, afecções e/ou distúrbios mediados por nadph oxidase.
BR112019023109-9A 2017-05-04 2018-05-04 Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo BR112019023109A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201721015787 2017-05-04
IN201721015787 2017-05-04
PCT/IB2018/053121 WO2018203298A1 (en) 2017-05-04 2018-05-04 Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors

Publications (1)

Publication Number Publication Date
BR112019023109A2 true BR112019023109A2 (pt) 2020-05-26

Family

ID=62245373

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019023109-9A BR112019023109A2 (pt) 2017-05-04 2018-05-04 Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo

Country Status (16)

Country Link
US (1) US20200247800A1 (pt)
EP (1) EP3619209A1 (pt)
JP (1) JP2020518624A (pt)
KR (1) KR20200013665A (pt)
CN (1) CN110914263A (pt)
AU (1) AU2018262528A1 (pt)
BR (1) BR112019023109A2 (pt)
CA (1) CA3062185A1 (pt)
CL (1) CL2019003107A1 (pt)
CO (1) CO2019013655A2 (pt)
EA (1) EA201992343A1 (pt)
MX (1) MX2019013148A (pt)
PE (1) PE20191789A1 (pt)
PH (1) PH12019502462A1 (pt)
SG (1) SG11201910172VA (pt)
WO (1) WO2018203298A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210087033A (ko) 2018-10-01 2021-07-09 젠자임 코포레이션 UDP 글리코실트랜스퍼라제 억제제로서의 티에노[3,2-b]피리딘 유도체 및 사용 방법
CN115215767B (zh) * 2021-04-16 2023-09-12 帕潘纳(北京)科技有限公司 制备2-氰基-3-乙氧基丙烯酸乙酯衍生物的方法
CN113292496B (zh) * 2021-05-17 2023-03-10 安徽联创生物医药股份有限公司 一种劳拉替尼中间体的合成方法
WO2023217764A1 (en) 2022-05-09 2023-11-16 Calliditas Therapeutics Suisse Sa Nox inhibitors for use in the treatment of alport syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004089412A1 (ja) * 2003-04-08 2006-07-06 三菱ウェルファーマ株式会社 特異的ｎａｄ（ｐ）ｈオキシダーゼ抑制剤
JP2007133750A (ja) * 2005-11-11 2007-05-31 Canon Inc 情報処理方法及び情報処理装置
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
FR2929276B1 (fr) * 2008-04-01 2010-04-23 Servier Lab Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166010A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
GB201104600D0 (en) * 2011-03-18 2011-05-04 Pronoxis Ab New compounds and medical uses
KR20180096644A (ko) * 2015-11-25 2018-08-29 이펙터 테라퓨틱스, 인크. Eif4a-억제 화합물 및 이에 관련된 방법

Also Published As

Publication number Publication date
CO2019013655A2 (es) 2020-04-01
CA3062185A1 (en) 2018-11-08
EA201992343A1 (ru) 2020-04-16
PE20191789A1 (es) 2019-12-24
MX2019013148A (es) 2019-12-18
EP3619209A1 (en) 2020-03-11
AU2018262528A1 (en) 2019-11-21
SG11201910172VA (en) 2019-11-28
US20200247800A1 (en) 2020-08-06
KR20200013665A (ko) 2020-02-07
CN110914263A (zh) 2020-03-24
CL2019003107A1 (es) 2020-03-13
PH12019502462A1 (en) 2020-06-29
JP2020518624A (ja) 2020-06-25
WO2018203298A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
BR112019023109A2 (pt) Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
BR112018075734A2 (pt) composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112018007977A2 (pt) inibidores de ferroportina inovadores
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BRPI0808824B8 (pt) derivado de pirazol piridina como inibidores de nadph oxidase, composição farmacêutica, e, uso de um derivado de pirazol piridina
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112015016793A2 (pt) compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim
BR112018068640A2 (pt) derivados de indolina substituídos como inibidores da replicação viral do dengue
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112019003557A2 (pt) derivados de oxopicolinamida, método de preparação dos mesmos e uso farmacêutico dos mesmos
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112018068956A2 (pt) derivados do composto indol substituídos como inibidores da replicação viral da dengue
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112017012846A2 (pt) derivados do amino tiadiazol como inibidores da nadph oxidase.
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
BR112017010645A2 (pt) derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos
BR112012020736A2 (pt) derivados de pirazolo diperidina como inibidores de nadph oxidase.
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]